Sarepta Therapeutics, Inc. vs. National Center of Neurology and Psychiatry et al.
Explore the PTAB proceeding IPR2021-01134 filed by Sarepta Therapeutics, Inc. on 2021-06-21. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2021-01134
Filing Date
2021-06-21
Accorded Filing Date
2021-06-21
Institution Decision Date
2022-01-07
Last Modified Date
2024-01-11
Proceeding Type
IPR
Termination Date
2022-06-14
Trial Status
Terminated
Parties & Counsel
Petitioner
Sarepta Therapeutics, Inc.
Represented By
Raich, Williamet alPatent Owner / Respondent
Patent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
0 Total
Proceeding Status
Terminated
Administrative Patent Judges (APJ Panel)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 17399 | Sheldon Witcoff | +1 312-715-1000 |
| 28042 | Charles Shifley | +1 312-463-5000 |
| 28175 | Joseph Potenza | +1 202-824-3000 |
| 29822 | Ernest Linek | +1 617-720-9600 |
| 29864 | Joseph Skerpon | +1 202-824-3000 |
| 31810 | Robert Altherr Jr | +1 202-824-3000 |
| 32141 | Sarah Kagan | +1 202-824-3151 |
| 32168 | Robert Resis | +1 312-463-5000 |
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ Radar 18 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 9,708,361 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,329,319 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,385,092 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,407,461 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,487,106 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,870,676 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,647,741 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,662,217 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,683,322 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2021017965 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,028,122 B1 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2021028468 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2021034017 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2023015105 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2025004293 | US Continuation / Sibling | View Official Patent → |
Sarepta Therapeutics, Inc. v. National Center of Neurology and Psychiatry et al.